Leucine-rich glioma-inactivated 1 versus contactin-associated protein-like 2 antibody neuropathic pain: clinical and biological comparisons
Pain is a under-recognized association of leucine-rich glioma-inactivated 1 (LGI1) and contactin-associated protein-like 2 (CASPR2) antibodies. Of 147 patients with these autoantibodies, pain was experienced by 17 of 33 (52%) with CASPR2- versus 20 of 108 (19%) with LGI1 antibodies (p = 0.0005), and...
Main Authors: | Ramanathan, S, Tseng, M, Davies, AJ, Uy, CE, Paneva, S, Mgbachi, VC, Michael, S, Varley, JA, Binks, S, Themistocleous, AC, Fehmi, J, Anziska, Y, Soni, A, Hofer, M, Waters, P, Brilot, F, Dale, RC, Dawes, J, Rinaldi, S, Bennett, DL, Irani, SR |
---|---|
Format: | Journal article |
Language: | English |
Published: |
Wiley
2021
|
Similar Items
-
Immunotherapy responsive neuropathic pain associated with LGI1 and CASPR2 antibodies
by: Ramanathan, S, et al.
Published: (2021) -
Immunotherapy-resistant neuropathic pain and fatigue predict quality-of-life in contactin-associated protein-like 2 antibody disease
by: Ceronie, B, et al.
Published: (2025) -
007 Immunotherapy responsive neuropathic pain associated with LGI1 and CASPR2 antibodies
by: Russell C Dale, et al.
Published: (2021-08-01) -
Contactin-2 associated protein (CASPR2) autoimmune neurological conditions: Detailed clinical phenotype and antibody quantification
by: Varley, J, et al.
Published: (2017) -
Association of leucine-rich glioma inactivated protein 1, contactin-associated protein 2, and contactin 2 antibodies with clinical features and patient-reported pain in acquired neuromyotonia
by: Vincent, A, et al.
Published: (2018)